On February 15, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that it has regained compliance with the Nasdaq Stock Market's listing standards regarding bid price and publicly held shares. The company received a letter from Nasdaq on February 13, 2024, confirming that it has met the minimum bid price and publicly held shares requirements, as per Nasdaq Listing Rules 5550(a)(2) and 5550(a)(4). Panbela also plans to present its equity compliance plan to the Nasdaq Hearings Panel. The company's pipeline includes clinical trials focusing on various cancers, with its lead assets being Ivospemin (SBP-101) and Flynpovi. Panbela's stock is traded on the Nasdaq under the symbol 'PBLA'. The announcement also included cautionary statements regarding forward-looking statements, outlining potential risks and uncertainties that could affect the company's future results and financial condition.

On February 15, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that it has regained compliance with the Nasdaq Stock Market's listing standards regarding bid price and publicly held shares. The company received a letter from Nasdaq on February 13, 2024, confirming that it has met the minimum bid price and publicly held shares requirements, as per Nasdaq Listing Rules 5550(a)(2) and 5550(a)(4). Panbela also plans to present its equity compliance plan to the Nasdaq Hearings Panel. The company's pipeline includes clinical trials focusing on various cancers, with its lead assets being Ivospemin (SBP-101) and Flynpovi. Panbela's stock is traded on the Nasdaq under the symbol 'PBLA'. The announcement also included cautionary statements regarding forward-looking statements, outlining potential risks and uncertainties that could affect the company's future results and financial condition.